Treatment of chronic myelogenous leukemia

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Christine Kujak, Jill M Kolesar

Abstract

Treatment options for chronic-phase chronic myelogenous leukemia (CML) based on medication-resistant mutations in BCR-ABL are reviewed. Imatinib, nilotinib, and dasatinib are first-line therapies for chronic-phase CML. Nilotinib or dasatinib can be used as first- or second-line treatment, with nilotinib preferred in patients with BCR-ABL F317 and V229 mutations and dasatinib in patients with Y253H, E255, and F359 mutations. All three medications are associated with neutropenia, thrombocytopenia, and anemia; the reported rates varied but ranged from 38% to 90% in Phase III studies. Although less data are available for bosutinib, the drug can be used as second-line therapy and is effective against F317L, Y253H, and F359 mutations. Mutations at position T315I are generally resistant to all of these tyrosine kinase inhibitors (TKIs) but may respond to ponatinib or omacetaxine. The choice of third-line therapy can be driven by mutational analysis or patient-specific characteristics. While ponatinib and omacetaxine have activity in patients with T351I mutations, they have not been directly compared. Differences in patient characteristics and adverse-effect profiles may also aid in the selection of appropriate therapy. Several TKIs ar...Continue Reading

References

Mar 15, 2003·The New England Journal of Medicine·Stephen G O'BrienUNKNOWN IRIS Investigators
May 15, 2003·The American Journal of Cardiology·Nanette Kass Wenger
Jul 17, 2004·Science·Neil P ShahCharles L Sawyers
Feb 16, 2005·Cancer Cell·Ellen WeisbergJames D Griffin
Nov 3, 2007·The Lancet Oncology·Jane F Apperley
Jul 23, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jamshid S KhorashadDavid Marin
Dec 17, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sara RedaelliFrank Boschelli
Aug 5, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Timothy HughesAndreas Hochhaus
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David MarinJamshid S Khorashad
May 15, 2010·Thrombosis Research·Michael B Streiff, UNKNOWN National Comprehensive Cancer Center Network
Jun 8, 2010·The New England Journal of Medicine·Giuseppe SaglioUNKNOWN ENESTnd Investigators
Jun 8, 2010·The New England Journal of Medicine·Hagop KantarjianMichele Baccarani
Jun 26, 2010·International Journal of Hematology·Tadashi NagaiNoriko Usui
May 4, 2011·American Journal of Hematology·Prasanth GanesanManjunath Nandennavar
Sep 6, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jorge E CortesCarlo Gambacorti-Passerini
Oct 18, 2013·Leukemia Research·Simona SoveriniNeil P Shah
Nov 5, 2013·The New England Journal of Medicine·J E CortesUNKNOWN PACE Investigators

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.